Saturday, May 25, 2024
HomeIndustriesBiotechnology

Biotechnology

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Psilera Inc. (“Psilera”), a Florida-based biotechnology company developing non-hallucinogenic derivatives of psychedelic compounds and outpatient delivery methods for the treatment of anxiety, substance abuse,...

Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19

Roche Announced that the European Commission has extended the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are...

Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe

Advicenne a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that...

Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Prometheus Biosciences, Inc. a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic...

Aphex BioCleanse Systems Engages Milestone Management Services

Aphex BioCleanse Systems, Inc., a forward-thinking, publicly traded company, announced it has reached an agreement to engage Milestone Management Services to join their Corporate...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics